TSP-1: A mediator of sepsis-induced lung injury
TSP-1:脓毒症引起的肺损伤的介质
基本信息
- 批准号:7636826
- 负责人:
- 金额:$ 13.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-01 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Lung InjuryAdult Respiratory Distress SyndromeAffectAreaBiological MarkersBlood PlateletsBlood VesselsBronchoalveolar Lavage FluidCaringCellsClinicalClinical ResearchClinical SciencesCoagulation ProcessComplexCoupledCritical IllnessDataDevelopmentDiseaseEducational CurriculumEpithelialEquilibriumEventEvolutionFunctional disorderFundingGeneticGenetic PolymorphismGenetic VariationGenotypeGoalsGrantHospitalsHumanIn VitroIncidenceIndividualInfectionInflammationInflammatoryInjuryInstitutionLungLung diseasesMediatingMediator of activation proteinMedicineMentorsOrganOrgan failureOutcomePathologicPatientsPhysiologicalProcessProperdinProteinsPublic HealthResearchResearch PersonnelResolutionResourcesRiskRoleScienceSepsisSerumSurfaceSyndromeTGFB1 geneTHBS1 geneThrombospondin 1TrainingTransforming Growth Factor betaTransforming Growth FactorsUnited StatesWorkWound Healingcareerclinically relevantcollegecytokinedesignexperiencelung injurymortalityprogramsrepairedresponseseptictertiary caretool
项目摘要
DESCRIPTION (provided by applicant):
This proposal represents a five-year curriculum and research plan that is designed to transition the candidate from his current mentored-bench research focus to one of independent investigator driven clinical research. The plan is five years in duration to facilitate the appropriate class work as well as the execution of the specific research objectives. Broadly, the main objectives are to confirm current in vitro hypotheses in humans with clinical signs of sepsis and complete coursework in clinical research sciences. The candidate's current research has centered on the role of inflammatory cell recruitment in lung disease. Sepsis has a very high associated mortality and its incidence may be rising. Lung injury is one of the more common organ dysfunctions present in severe sepsis. Transforming Growth Factor Beta (TGFb) is known to be present in early lung injury and may be serving to repair the initial pulmonary insult. Vascular events known to be important in sepsis include inflammation and initiation of the coagulation cascade. The balance between inflammation and repair caused by these cascades may be critical to resolution of lung injury. As a result, the end products of these cascades may have a potential role in affecting the course of organ dysfunction in severe sepsis. Thrombospondin-1 (TSP-1) is increased in human sepsis, but its implications are not fully understood. Because TSP-1 is known to interact with and activate latent TGF-beta, its presence may serve to initiate the TGF-beta response necessary to repair acute lung injury in severe sepsis. Specific Aim: To investigate whether TSP-1 is important in modulating the course of sepsis-induced acute lung injury. Hypothesis 1.1: In human sepsis, increased TSP-1 levels will be associated with subsequent increases in TGFbeta1. Hypothesis 1.2: In human sepsis, increased TSP-1 levels will be associated with a lower incidence and shorter course of lung-injury. Hypothesis 1.3: Patients with the Asn682Ser polymorphism in the TSP-1 gene will have a higher incidence of and a more severe course of lung injury. Through these studies, the importance, clinical relevance and potential implications of TSP-1 and TGF-beta interactions on the development of ARDS in septic patients can be determined. The development portion of this grant is designed to facilitate the applicant's career goals of becoming an independently funded clinical researcher in the area ARDS and sepsis. The combined resources of this institution (tertiary care hospital, GCRC and College of Medicine and Public Health) will be available to the candidate to achieve these goals.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAEEM A ALI其他文献
NAEEM A ALI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAEEM A ALI', 18)}}的其他基金
TSP-1: A mediator of sepsis-induced lung injury
TSP-1:脓毒症引起的肺损伤的介质
- 批准号:
7037113 - 财政年份:2006
- 资助金额:
$ 13.27万 - 项目类别:
TSP-1: A mediator of sepsis-induced lung injury
TSP-1:脓毒症引起的肺损伤的介质
- 批准号:
7463528 - 财政年份:2006
- 资助金额:
$ 13.27万 - 项目类别:
TSP-1: A mediator of sepsis-induced lung injury
TSP-1:脓毒症引起的肺损伤的介质
- 批准号:
7906763 - 财政年份:2006
- 资助金额:
$ 13.27万 - 项目类别:
TSP-1: A mediator of sepsis-induced lung injury
TSP-1:脓毒症引起的肺损伤的介质
- 批准号:
7283063 - 财政年份:2006
- 资助金额:
$ 13.27万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:














{{item.name}}会员




